Improved splicing of adeno-associated viral (AAV) capsid protein-supplying pre-mRNAs leads to increased recombinant AAV vector production.
Adeno-associated viral (AAV) capsid proteins, thought to be a rate-limiting step in the production of recombinant AAV (rAAV), are translated from spliced mRNAs. Improvement of the native AAV nonconsensus donor sequence increases splicing yet leaves the relative levels of VP1- and VP2/3-encoding mRNAs unchanged, and thus provides a means to increase delivery of correct ratios of AAV capsid proteins. This effect is independent of the AAV serotype used, and occurs whether the rep and cap genes supplied in trans are on the same or separate expression vectors. In the split-vector system, replacement of the more traditionally used cytomegalovirus promoter with that of the AAV5 P41 promoter allowed for even greater levels of splicing, and together with an improved intron donor, led to a 10- to 15-fold increase in the levels of splicing, rAAV production, and transduction compared with levels achieved by traditional cotransfection methods. Thus, the enhancement of splicing presents a useful method to enhance rAAV production via transient transfection.
Farris
K David
KD
Department of Molecular Microbiology and Immunology, University of Missouri-Columbia School of Medicine, Life Sciences Center, Columbia, MO 65211, USA.
Pintel
David J
DJ
D002213:Capsid / Q000378:metabolism*; D002460:Cell Line; D000229:Dependovirus / Q000235:genetics* / Q000378:metabolism; D005822:Genetic Vectors; D006801:Humans; D016133:Polymerase Chain Reaction; D012326:RNA Splicing; D012333:RNA, Messenger / Q000235:genetics*; D011995:Recombination, Genetic
D012333:RNA, Messenger
J Virol Methods. 2003 Dec;114(1):1-10
14599673
J Virol. 2000 Dec;74(24):11456-63
11090141
J Virol. 1988 Sep;62(9):3356-63
2841488
Mol Cell Biol. 1998 Oct;18(10):5921-9
9742109
Mol Cell Biol. 2002 Jun;22(11):3639-52
11997501
Virology. 1991 Mar;181(1):22-34
1825251
J Virol. 1988 Aug;62(8):2745-54
2839699
Hum Gene Ther. 2002 Nov 1;13(16):1935-43
12427305
EMBO J. 2003 Apr 1;22(7):1716-24
12660177
J Virol. 1997 Jul;71(7):5236-43
9188591
Virology. 2002 Feb 15;293(2):345-55
11886255
J Virol. 1997 Sep;71(9):6816-22
9261406
J Virol. 1998 Mar;72(3):2224-32
9499080
Genes Dev. 1992 Jun;6(6):1107-19
1592259
J Virol. 2006 Jul;80(13):6559-67
16775342
Virology. 2001 Dec 5;291(1):140-51
11878883
Brief Funct Genomic Proteomic. 2008 Jul;7(4):303-11
18632744
Virology. 1966 Jun;29(2):353-7
5943543
Proc Natl Acad Sci U S A. 1966 Jun;55(6):1467-74
5227666
Proc Natl Acad Sci U S A. 1967 Oct;58(4):1410-5
4295829
J Virol. 1997 Mar;71(3):1897-905
9032320
EMBO J. 1991 Dec;10(12):3941-50
1657596
J Virol Methods. 2006 Dec;138(1-2):85-98
16950522
Gene Ther. 2002 Sep;9(18):1199-206
12215886
J Virol Methods. 2006 Nov;137(2):193-204
16860883
Biochem Biophys Res Commun. 2000 Sep 24;276(2):559-63
11027513
J Virol. 2002 Dec;76(24):12435-47
12438569
J Virol. 1998 Jul;72(7):5472-80
9621003
Proc Natl Acad Sci U S A. 1990 Mar;87(6):2211-5
2156265
J Virol. 2006 Aug;80(16):7807-15
16873238
Virology. 2005 Apr 25;335(1):10-21
15823602
J Virol. 2000 Nov;74(21):9878-88
11024114